Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Adnexus Therapeutics

2002 FOUNDED
M&A STATUS
101-200 EMPLOYEES
M&A LATEST DEAL TYPE
$430M LATEST DEAL AMOUNT
Description

Developer of Adnectins biologics/medicines in the United States. The company's product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases.

Formerly Known As
Compound Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 100 Beaver Street
  • Waltham, MA 02453
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Adnexus Therapeutics’s full profile, request a free trial.

Adnexus Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 24-Sep-2007 $430M 000.00 00000 Completed Startup
6. IPO 21-Aug-2007 000.00 Cancelled Clinical Trials - Phase 2
5. Early Stage VC 07-Aug-2007 000.00 000.00 Completed Startup
4. Early Stage VC (Series B) 20-Jun-2006 0000 000.00 Completed Startup
3. Convertible Debt 24-May-2006 00.00 000.00 Completed Startup
2. Early Stage VC 28-Dec-2004 $15.6M $22.1M Completed Startup
1. Early Stage VC (Series A) 03-Apr-2003 $6.5M $6.5M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Adnexus Therapeutics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Applied Genomic Technology Capital Fund Venture Capital Minority 000 0000 000000 0
Atlas Venture Venture Capital Minority 000 0000 000000 0
Flagship Pioneering Venture Capital Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
Polaris Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Adnexus Therapeutics Executive Team (9)

Name Title Board
Seat
Contact
Info
Bruce Silver MD Medical Director
Cliff Bechtold Vice President, Strategic Operations

7 Former Executives

You’re viewing 2 of 9 executives. Get the full list »